Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves Audit LLP as auditor to the Company. The appointment of Kreston Reeves Audit follows a restructuring of the audit practice of Kreston Reeves LLP, the Company’s former auditor, and will be subject to approval by shareholders at the next Annual General Meeting of the Company.
Nuformix appoints Kreston Reeves Audit as new auditor
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Latest Company News
Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons.
Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions.
Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners.
Nuformix has reported positive inhaled NXP002 preclinical data, supporting pulmonary exposure, target engagement and further development planning.
Pulmonary fibrosis creates long-term demand for treatments, respiratory equipment and patient-support services as care needs increase over time.
Nuformix reported a reduced interim loss and a significantly improved cash position for the six months ended 31 March 2026, supported by successful fundraisings and progress with NXP002, including FDA Orphan Drug Designation in IPF.
